

CTI - Neurological Disorders February 2010

Adis Clinical Trials Insight: Ongoing Trials – Status Tracking February 2010

The table below highlights the ongoing trials whose status has changed during February 2010

Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
1 700048117	Antiparkinsonians	Active, no longer recruiting	IV	Antiparkinsonians: therapeutic use Parkinsonism, essential tremor Assessing changes in prescribing pattern after DaTSCANTM imaging in patients with clinically uncertain disease	GE Healthcare
2 700016396	Atomoxetine	Completed	II	Atomoxetine: therapeutic use Huntington's disease Effects on inattention symptoms in patients with early disease	Eli Lilly
3 700052427	BMS-708163 Donepezil	Recruiting	I	BMS 708163 + donepezil: pharmacokinetics Potential pharmacokinetic interactions In volunteers	Bristol-Myers Squibb
4 700052335	BMS-708163 Galantamine	Recruiting	I	Galantamine +/- BMS 708163: pharmacokinetics Potential pharmacokinetic interactions In healthy men and postmenopausal women	Bristol-Myers Squibb
5 700049775	Dimebolin	Completed	I	Dimebolin: pharmacokinetics Comparing transdermal solution relative to the immediate release formulation In volunteers	Medivation, Pfizer
6 700042448	Dimebolin	Active, no longer recruiting	III	Dimebolin: adverse reactions Various toxicities In patients with mild to moderate Alzheimer's disease	Medivation, Pfizer
7 700049592	Donepezil	Active, no longer recruiting	II	Donepezil: pharmacodynamics Effect on cerebrospinal fluid acetylcholine levels In volunteers	Pfizer
8 700031958	Gabapentin	Active, no longer recruiting	III	Gabapentin: adverse reactions Various toxicities In Japanese adolescents, children and infants with partial seizures	Pfizer
9 700048319	Gemfibrozil SAM-531	Completed	I	SAM-531 + gemfibrozil: pharmacokinetics Potential Pharmacokinetic Interaction In volunteers	Wyeth

CTI - Neurological Disorders February 2010

Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
10 700050979	GSK-239512	Recruiting	II	GSK 239512: therapeutic use Alzheimer's disease In patients with mild to moderate disease	GlaxoSmithKline
11 700024290	Interferon-beta-1b	Completed	III	Interferon beta-1b: therapeutic use Multiple sclerosis In patients with a first clinical demyelinating event and in those with onset of relapsing-remitting disease	Bayer
12 700024624	Iscomatrix V-950	Active, no longer recruiting	I	V 950: adverse reactions Various toxicities With or without iscomatrix adjuvant, in patients with Alzheimer's disease	Merck & Co, Merck Sharp & Dohme
13 700028202	Levetiracetam	Active, no longer recruiting	II	Levetiracetam: adverse reactions Various toxicities In children and adolescents with epilepsy	UCB
14 700043551	Levodopa/carbidopa	Active, no longer recruiting	III	Levodopa/carbidopa: therapeutic use Parkinson's disease In patients with idiopathic disease	IMPAX Laboratories
15 700046180	Levodopa/carbidopa	Recruiting	II	Levodopa/carbidopa: adverse reactions Various toxicities	Intec Pharma
16 700012757	Liatermin	Completed	IV	Liatermin: adverse reactions Various toxicities Drug withdrawal in patients previously treated with intraputaminial infusions	Amgen
17 700036892	MABT-5102A	Active, no longer recruiting	I	MABT 5102A: adverse reactions Various toxicities In patients with mild to moderate Alzheimer's disease	Genentech
18 700048386	Melatonin	Recruiting	II	Melatonin: therapeutic use Sleep disorders In patients with refractory epilepsy	
19 700042398	Memantine	Active, no longer recruiting	III	Memantine: adverse reactions Various toxicities In patients with moderate to severe Alzheimer's disease	Lundbeck A/S

CTI - Neurological Disorders February 2010

Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
20 700019491	Memantine	Completed	IV	Memantine: therapeutic use Aggression, agitation In patients with Alzheimer's disease	Lundbeck A/S
21 700042413	Memantine	Active, no longer recruiting	III	Memantine: pharmacodynamics Effect on cognition and behavioural symptoms In patients with moderate to severe Alzheimer's disease	Lundbeck A/S
22 700053339	Minocycline	Recruiting	I/II	Minocycline: therapeutic use Brain injuries In males with moderate and severe disease	
23 700028837	Natalizumab	Recruiting	I	Natalizumab: pharmacokinetics Comparison of subcutaneous, intramuscular and intravenous administration In patients with secondary-progressive multiple sclerosis	Biogen Idec, Elan Pharmaceuticals
24 700045137	Oxcarbazepine	Recruiting	III	Oxcarbazepine: adverse reactions Various toxicities In patients with refractory partial epilepsy on up to two concomitant antiepileptic medications	Supernus Pharmaceuticals
25 700041965	Perampanel	Completed	II	Perampanel: adverse reactions Various toxicities In Japanese patients with refractory partial seizures uncontrolled with other anti-epileptic drugs	Eisai, Eisai Inc, Eisai Medical Research
26 700025404	PF-5236806 QS-21	Recruiting	II	ACC 001: adverse reactions Various toxicities Phase II trial of efficacy, tolerability and immunogenicity, with or without adjuvant QS 21, in patients with mild to moderate disease	Elan Pharmaceuticals, Wyeth
27 700050950	Piribedil Pramipexole Ropinirole	Recruiting	III	Piribedil vs pramipexole, ropinirole: therapeutic use Parkinson's disease Effects on vigilance and cognitive function	Desitin Pharmaceuticals GmbH
28 700029388	PRX-03140	Discontinued	II	PRX 03140: therapeutic use Alzheimer's disease Phase IIb study in patients on stable donepezil therapy	EPIX Pharmaceuticals

CTI - Neurological Disorders February 2010

Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
29 700035246	PYM-50028	Not yet recruiting	II	PYM 50028: therapeutic use Parkinson's disease Phase IIa trial	Phytofarm
30 700031158	RN-1219	Active, no longer recruiting	I	RN 1219: adverse reactions Various toxicities In Japanese patients with mild to moderate Alzheimer's disease	Pfizer
31 700017055	Rosiglitazone	Completed	III	Rosiglitazone: therapeutic use Alzheimer's disease Adjunctive therapy in patients with mild-to-moderate disease	GlaxoSmithKline
32 700015892	Rosiglitazone	Completed	II	Rosiglitazone: adverse reactions Various toxicities Phase II study in patients with mild-to-moderate Alzheimer's disease	GlaxoSmithKline

For further information, please call +44 (0) 20 7981 0765 or send an e-mail to clientsupport@wolterskluwer.com.